About
Alloteratx develops allogeneic (off-the-shelf) CAR-T cell therapies targeting T-cell cancers and autoimmune indications, advancing treatments for T-cell malignancies such as T-cell acute lymphoblastic leukemia and lymphomas.
Explore Alloteratx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.